ANG021

ANG021 is a preclinical-stage, orally delivered enzyme therapeutic being developed by Anagram Therapeutics for the treatment of malabsorptive syndromes. It is specifically engineered to break down complex carbohydrates in the gastrointestinal tract of patients who suffer from malabsorption abnormalities, often as a result of pancreatic dysfunction. By supplementing or replacing deficient digestive enzymes, ANG021 aims to facilitate proper nutrient absorption and prevent the gastrointestinal complications associated with carbohydrate malabsorption. The drug is part of a broader pipeline of enzyme replacement therapies designed to address nutrient metabolism disorders.